Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). EyePoint announced topline LUCIA Phase 3 data for DURAVYU in wet AMD, a potentially value-defining clinical milestone.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- EyePoint announced topline LUCIA Phase 3 data for DURAVYU in wet AMD, a potentially value-defining clinical milestone
- Results are detailed in Exhibit 99.1, requiring review for efficacy, safety, and regulatory implications
- Updated investor presentation filed as Exhibit 99.2, likely providing management’s interpretation and development outlook
Item EX-99.1 · Exhibit EX-99.1
- LUCIA missed its primary non-inferiority endpoint versus aflibercept, materially weakening DURAVYU’s wet AMD approval and commercial path
- Treatment burden fell 38%, with 52% of eyes supplement-free and 71% needing zero or one supplement through Week 56
- LUGANO also missed its primary endpoint, indicating consistent efficacy risk across both pivotal wet AMD trials
- DME remains the strategic focus, with Phase 3 COMO and CAPRI topline results expected in Q4 2027
- DURAVYU’s favorable redosing safety profile supports continued development, but FDA approval remains uncertain
Item EX-99.2 · Exhibit EX-99.2
- LUCIA missed wet AMD non-inferiority: BCVA change +2.5 letters vs +6.1 for aflibercept, difference -3.7 letters
- Primary failure materially weakens DURAVYU’s wet AMD approval prospects despite visual improvement
- Treatment burden improved: 3.3 vs 5.3 injections after loading, 38% fewer injections, nominal p<0.0001
- Durability signal: 52% remained supplement-free through Week 56, while pooled trials showed 40% fewer injections
- EyePoint is shifting emphasis to DME trials COMO and CAPRI, with topline results expected in 4Q 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.